Browsing by Author "Delgado González, Julio"

Now showing items 1-3 of 3

ATM germline variants in a young adult with chronic lymphocytic leukemia: 8 years of genomic evolution

Royo, Romina; Magnano, Laura; Delgado González, Julio; Ruiz Gil, Sara; Gelpí, Josep Lluís; Heyn, Holger; Taylor, Malcom A.; Stankovic, Tatjana; Puente, Xosé S.; Nadeu, Ferran; Campo, Elias (Nature Research, 2022)
Systems biology drug screening identifies statins as enhancers of current therapies in chronic lymphocytic leukemia

Gimenez, Neus; Tripathi, Rupal; Giró, Ariadna; Rosich, Laia; López-Guerra, Mónica; López-Oreja, Irene; Playa-Albinyana, Heribert; Arenas, Fabián; Mas, José Manuel; Pérez-Galán, Patricia; Delgado González, Julio; Campo, Elias; Farrés, Judith; Colomer Pujol, Dolors (Nature Research, 2020)

Chronic lymphocytic leukemia (CLL) is a B lymphoid malignancy highly dependent on the microenvironment. Despite new targeted therapies such as ibrutinib and venetoclax, disease progression and relapse remain an issue. CLL ...
Tisagenlecleucel (chimeric antigen receptor T-cells targeting CD19) for patients with relapsed/refractory B-cell acute lymphoblastic leukemia: asystematic review and cost-utility analysis from a Spanish perspective

Delgado González, Julio (2020)

Patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (ALL) have a poor prognosis with conventional therapies. In the summer of 2018, the European Medicines Agency approved tisagenlecleucel (tisa-cel, ...

Now showing items 1-3 of 3

Search DSpace

Compliant to Partaking